Significant efficacy of 2-chlorodeoxyadenosine± rituximab in the treatment of splenic marginal zone lymphoma (SMZL): Extended follow-up

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2434-2438

  Cervetti, G ^a   Galimberti, S ^a   Pelosini, M ^a   Ghio, F ^a   Cecconi, N ^a   Petrini, M ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cladribrine; MRD; Rituximab; Splenic marginal zone lymphoma

Indexed keywords

ACICLOVIR; ALBUMIN; BETA 2 MICROGLOBULIN; CHLORAMBUCIL; CLADRIBINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOXORUBICIN; FLUCONAZOLE; FLUDARABINE; HEMOGLOBIN; IDARUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; LACTATE DEHYDROGENASE; PARACETAMOL; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; STEROID; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RATING SCALE; RETROSPECTIVE STUDY; SCORING SYSTEM; SECOND CANCER; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA; STOMACH CARCINOMA; TREATMENT DURATION;

CLADRIBRINE; MRD; RITUXIMAB; SPLENIC MARGINAL ZONE LYMPHOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; SPLENIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84883435898     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt181     Document Type: Article

References (26)

1. Troussard X, Valensi F, Duchayne E et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC). Br J Haematol 1996; 93: 731-736.
2. Nathwani B, Anderson J, Armitage J et al. Marginal zone B cell lymphoma: a clinical comparison of nodal and mucosa associated lymphoid tissue types. Non- Hodgkin's Lymphoma Classification Project. J Clin Oncol 1999; 17: 2486-2492.
3. Berger F, Felman P, Thieblemont C et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000; 95: 1950-1956.
4. Thieblemont C, Felman P, Callet-Bauchu E et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003; 4: 95-103.
5. Franco V, Florena AM, Stella M et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone lymphoma with or without villous lymphocytes. Cancer 2001; 91: 294-301.
6. Andouin J, Le Tourneau A, Molina T et al. Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes. Br J Haematol 2003; 122: 404-412.
7. Chacon J, Mollejo M, Munoz E et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002; 100: 1648-1654.
8. Arcaini L, Lazzarino M, Colombo N et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006; 107: 4643-4649.
9. Hermine O, Lefrere F, Bronowicki JP et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94.
10. Keladi C, Rollor F, Park S et al. Response to antiviral treatment in hepatitis C virus associated marginal zone lymphomas. Leukemia 2004; 18: 1711-1716.
11. Bolam S, Orchard J, Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol 1997; 99: 158-161.
12. Lefrere F, Hermine O, Belanger C et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 2000; 14: 573-575.
13. Iannitto E, Minardi V, Calvaruso G et al. Deoxycoformycin (penttostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. Eur J Haematol 2005; 75: 130-135.
14. Virchis A, Mehta A. Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorodeoxyadenosine (2-chlorodeoxyadenosine). Br J Haematol 1998; 100: 609.
15. Lefrere F, Hermine O, Francois S et al. Lack of efficacy of 2-chlorodeoxyadenosine in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma 2000; 40: 113-117.
16. Riccioni R, Caracciolo F, Galimberti S et al. Low dose 2-chlorodeoxyadenosine schedule activity in splenic marginal zone lymphomas. Hematol Oncol 2003; 21: 163-168.
17. Arcaini L, Orlandi E, Scotti M et al. Combination of rituximab, cyclophosphamide and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma 2004; 4: 250-252.
18. Bennett M, Sharma K, Yegena S et al. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica 2005; 90: 856-858.
19. Tsimberidou AM, Catovsky D, Schlette E et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with Rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006; 107: 125-135.
20. Fabbri A, Gozetti A, Lazzi S et al. Activity of rituximab in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia. Clin Lymphoma Myeloma 2006; 6: 496-499.
21. Galimberti S, Brizzi S, Mameli F et al. An advantageous method to evaluate IgH rearrangement and its role in minimal residual disease detection. Leuk Res 1999; 23: 921-929.
22. Bennet M, Schechter GP. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. Semin Hematol 2010; 47: 143-147.
23. Kalpadakis C, Pangalis GA, Dimopoulou MN et al. Rituximab monotherapy is higly effective in splenic marginal zone lymphoma. Hematol Oncol 2007; 25: 127-131.
24. Orciuolo E, Buda G, Sordi E et al. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res 2010; 34(2): 184-9. Epub 2009 May 2.
25. Cervetti G, Galimberti S, Sordi E et al. Significant efficay of 2-chlorodeoxyadenosine with or without Rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol 2010; 21(4): 851-854.
26. Cervetti G, Galimberti S, Andreazzoli F et al. Rituximab as treatment of minimal residual disease in hairy cell leukaemia: extended follow-up. Br J Haemat 2008; 143: 296-298.